These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 11244325)

  • 1. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
    Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F
    Oncology; 2001; 60(2):116-22. PubMed ID: 11244325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors.
    Frustaci S; Buonadonna A; Romanini A; Comandone A; Dalla Palma M; Gamucci T; Verusio C; Lionetto R; Dani C; Casali P; Santoro A
    Tumori; 1999; 85(4):229-33. PubMed ID: 10587022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
    Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
    J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
    Lück HJ; Du Bois A; Thomssen C; Lisboa B; Untch M; Köhler G; Hecker D
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):34-7. PubMed ID: 9144689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
    Bunnell CA; Thompson L; Buswell L; Berkowitz R; Muto M; Sheets E; Shulman LN
    Cancer; 1998 Feb; 82(3):561-6. PubMed ID: 9452275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
    Hoffman PC; Masters GA; Drinkard LC; Krauss SA; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):11-5. PubMed ID: 8677441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
    Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
    Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer.
    Lauria R; Ferrari E; Tramontana S; Morabito A; Perrone F; Maffeo A; Fiorentino R; Casella G; Iodice F; Ricchi P; Carlomagno C; Varriale E; De Placido G; De Placido S; Bianco AR; Pignata S
    Oncology; 1999; 56(4):267-73. PubMed ID: 10343189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
    Miglietta L; Amoroso D; Bruzzone M; Granetto C; Catsafados E; Mammoliti S; Guarneri D; Pedulla F; Foglia G; Ragni N; Martini MC; Brema F; Addamo G; Moraglio L; Pastorino G; Boccardo F
    Oncology; 1997; 54(2):102-7. PubMed ID: 9075779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: a phase I study.
    Hoffman PC; Masters GA; Drinkard LC; Krauss SA; Samuels BL; Golomb HM; Vokes EE
    Ann Oncol; 1996 Mar; 7(3):314-6. PubMed ID: 8740798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
    Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
    J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.